These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33479025)

  • 1. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
    Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
    Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
    Patel SP; Petroni GR; Roszik J; Olson WC; Wages NA; Chianese-Bullock KA; Smolkin M; Varhegyi N; Gaughan E; Smith KT; Haden K; Hall EH; Gnjatic S; Hwu P; Slingluff CL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
    Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
    Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM
    J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
    Vavolizza RD; Petroni GR; Mauldin IS; Chianese-Bullock KA; Olson WC; Smith KT; Dengel LT; Haden K; Grosh WW; Kaur V; Varhegyi N; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
    J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
    Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
    Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
    Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
    Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.
    Salerno EP; Shea SM; Olson WC; Petroni GR; Smolkin ME; McSkimming C; Chianese-Bullock KA; Slingluff CL
    Cancer Immunol Immunother; 2013 Jul; 62(7):1149-59. PubMed ID: 23657629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
    Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
    Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
    Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
    Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
    Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
    Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
    Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
    Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
    Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
    Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
    [No Abstract]   [Full Text] [Related]  

  • 19. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
    Rosenberg SA; Yang JC; Kammula US; Hughes MS; Restifo NP; Schwarz SL; Morton KE; Laurencot CM; Sherry RM
    J Immunother; 2010; 33(6):626-9. PubMed ID: 20551834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.